 Geneva, Switzerland, January 7, 2021 Addex Therapeutics Ltd SIX: ADXN and Nasdaq: ADXN, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the pricing of an underwritten global offering of 6,000,000 registered shares the New Shares including shares in the form of American Depositary Shares, or ADSs at a public offering price of approximately CHF1.47 per share or 10.00 per ADS. Each ADS represents the right to receive six shares of Addex. The aggregate gross proceeds from the offering are expected to be 10.0 million, before deducting the underwriting discounts and commissions and offering expenses payable by Addex. The offering is expected to close on or about January 11, 2021, subject to satisfaction of customary closing conditions. 